A Phase 1 interventional study of N-thymidine and Urine Collection in Tetralogy of Fallot and Double Outlet Right Ventricle, sponsored by Weill Medical College of Cornell University. Recruiting at 4 sites in United States. Open to participants aged 30 Days to 100 Days. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Weill Medical College of Cornell University · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Tetralogy of Fallot with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Tetralogy of Fallot · United States.
Among the 32 studies in Tetralogy of Fallot with a site in United States, this one is the 10th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2022, is one of 3 in phase 1, reaches primary completion later than 11 of the 11 other live ones, and was the 23rd registered.
92 studies on the registry are indexed under Tetralogy of Fallot; 25 are open to participants now.
Browse Tetralogy of Fallot studies →7 of the 32 studies in Tetralogy of Fallot with a site in United States are open now. Recruiting first, the newest first:
Boston Children's Hospital · Sites in United States
Ages 1 days–17 yrs
PECA Labs · Sites in United States
Ages 0–22
Leiden University Medical Center · Sites in United States, Germany, Netherlands and 2 more countries
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Edwards Lifesciences · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Tetralogy of Fallot studies recruiting now, 8 (47%) set no upper age limit and 9 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.
This study: 30 Days to 100 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 4 1
First in 2004; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 50 across 50 interventional studies indexed under Tetralogy of Fallot.
Median enrollment 35 across the 20 interventional studies, 152 across the 12 observational. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 32 have an industry lead sponsor. The 10 most frequent:
Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.
Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.
Weill Medical College of Cornell University has 1 study filed under Tetralogy of Fallot — fewer than ten, so there is no comparison to draw.
3 of the studies in Tetralogy of Fallot with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05077774Medtronic CardiovascularHarmony TPV Post-Approval Study | 2026-11 |
| NCT02744677Edwards LifesciencesCOMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | 2026-12 |
| NCT07184476Boston Children's HospitalAssessment of Microvascular Circulation in the Pediatric Cardiac Surgery Patient | 2027-03-17 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Tetralogy of Fallot with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Heart failure is a common long-term complication in patients with congenital heart disease (CHD). Medical treatments to promote regeneration of new healthy heart muscle cells have the potential to provide new heart failure treatments for these patients. The development of such therapies is limited by the poor understanding of the ways in which heart muscles grow after birth. Investigators have learned that humans without heart disease generate new heart muscles cells up to the age of 20 years old and that this is decreased in patients with congenital heart disease like Tetralogy of Fallot. Investigators are trying to determine if treatment with a medicine called Propranolol can increase heart muscle cell proliferation and, with that, normalize heart growth. Investigators will examine discarded heart muscle tissue that is obtained during surgery for the presence of new heart muscle cells. Propranolol is approved by the Food and Drug Administration (FDA) to treat a certain kind of benign tumor in infants (hemangioma), but it is not currently approved by the FDA to increase heart muscle growth.
The criteria were revised on the registry on Oct 26, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The target dose of Propranolol hydrochloride for this study target dose for this study will be 1mg/kg PO x 3 doses per day. The concentration of propranolol solution is 20 mg/5 mL. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with propranolol will begin at 1 month of age and continue until 4 months of age or 24hrs prior to surgical repair, whichever comes first.
Other: N-thymidine · Other: Urine Collection · Procedure: Echocardiogram · Procedure: Cardiac MRI (CMR) · Drug: Propranolol Hydrochloride · Procedure: Physical Exam · Other: Specimen Collection
Placebo will be given in a volume that corresponds to the patient's weight. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with placebo will begin at 1 month of age and continue until 4 months of age or 24hrs prior to surgical repair, whichever comes first. There is no current standard of care for pharmacologic therapy for infants with Tetralogy of Fallot (ToF). As such, there are no alternative treatments, and the placebo group is standard of care.
Other: N-thymidine · Other: Urine Collection · Procedure: Echocardiogram · Procedure: Cardiac MRI (CMR) · Drug: Placebo · Procedure: Physical Exam · Other: Specimen Collection
15N-thymidine will be administered to patients in order to quantify cardiomyocyte proliferation. 15N-thymidine will be administered as 5 separate syringes. Each syringe will contain the recommended daily dose based on participants weight. Subjects will be given the labeled thymidine by mouth once a day for 5 consecutive days. The dosing will begin one week after starting the study drug.The caregiver (parent or nurse) will administer the labeled thymidine by mouth via a syringe once a day for 5 consecutive days. They will be provided with a diary to keep track of study drug dosing.
Also known as: Thymidine
Parents will be asked to keep a diary of the child's feeding and diaper changes during the administration of thymidine. To monitor how the labeled thymidine is processed in the body, investigators will analyze urine from the child's diapers. Each time a diaper is changed, a cotton ball will be placed in the diaper. At the next diaper change, this cotton ball will be removed from the diaper, placed in a Ziploc bag, and stored in the freezer. They will be collected and stored cotton balls starting with the first administration of thymidine until 24 hours after the last administration. The frozen cotton balls may be collected from the home by a nurse or brought by parent to the next clinic visit.
On Study Day 1 to obtain baseline assessment of cardiac size. A second research dedicated echocardiogram will be done after being anesthetized for surgery. Echocardiography is routinely performed to determine right ventricle (RV) structure of the heart and function in Tetrology of Fallot/ Pulmonary Stenosis (ToF/PS) and is non-invasive.
A limited study protocol will be performed using the feed-and-bundle technique at the time of study enrollment, The feed and bundle technique is utilized so that the infant will be as comfortable as possible and asleep during the procedure. This is done to prevent the risk of sedation and allow for a more natural sleep. The baby is undressed, prepared with ECG-leads and an oxygen saturation probe, and fed. With this "feed, swaddle, and sleep" technique, scanning times of 30-60 minutes can be achieved, which provides the stillness needed for accurate visualization of the heart. A second CMR, with the same limited study protocol, will be performed under general anesthesia prior to surgical repair. It does not pose any risk of radiation exposure and will not require IV placement or contrast administration for a limited assessement of the right ventricle.
For patients who are randomized to receive propranolol, The target dose for this study will be 3 mg/kg/day divided in 3 doses. The first dose will be given in the Pediatric Clinical and Translational Research Center (PCTRC) at 1mg/kg. Parents will administer propranolol (1 mg/kg po x 3 doses per day). Parents will be instructed to administer propranolol with feeding or soon after feeding, but not before feeding. families will also be given instructions for regarding 15N-thymidine dosing frequency and interval and provided with a log sheet to record administered and missed doses of propranolol and 15N-thymidine.
Also known as: Propranolol
For patients who are randomized to receive placebo, the first dose will be given in the Pediatric Translational Research Center (PCTRC) and will be based on the patients weight. Parents will administer placebo 3 doses per day. Treatment with placebo will begin at 1 month of age and continue until 4 months of age or 24hrs prior to surgical repair, whichever comes first.
On Study Day 1; monthly until surgery in conjunction with patient's clinical cardiology appointment; and at the time of surgery. Will include vital signs.
On the morning of surgery, after IV access is obtained for anesthesia 2 ml of blood will be collected for analysis. A small piece of heart tissue and fat that has already been removed during surgery will be collected for analysis.
Cardiomyocyte Division
To quantify cardiomyocyte division, investigators will utilize previously established MIMS (membrane introduction mass spectrometry) approach. Briefly, investigators will administer 5 enteral doses of 15N-thymidine to all patients at 1 month after birth. Cardiomyocytes that have undergone DNA replication after the intake of 15N-thymidine will incorporate the stable isotope into their DNA.
Time frame: At the time of complete surgical repair, at approximately 3-9 months old, it is expected that a piece of RV myocardium will be resected. This tissue will be collected and analyzed using a multiple isotope mass spectrometer.
Hypertrophy as assessed by echocardiography
Analysis of the impact of propranolol on Right Ventricle Myocardial Volume
Time frame: At 1 month and at time of surgery
Hypertrophy as assessed by Cardiac MRI
Analysis of the impact of propranolol on Right Ventricle Myocardial Volume
Time frame: At 1 month and at time of surgery
Hypertrophy assessed by microscopy
Analysis of the impact of propranolol on cardiomyocytes cross sectional area
Time frame: At time of Surgery
Plan to share: No
Started Dec 2022 (actual). Primary completion is estimated for Dec 2030, 96 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Propranolol
Weill Medical College of Cornell University →